Title
Progress Toward Long-Term Survivors of Glioblastoma
Date Issued
01 July 2019
Access level
metadata only access
Resource Type
journal article
Author(s)
Cantrell J.N.
Waddle M.R.
Rotman M.
Peterson J.L.
Heckman M.G.
Quiñones-Hinojosa A.
Rosenfeld S.S.
Brown P.D.
Trifiletti D.M.
Mayo Clinic
Publisher(s)
Elsevier Ltd
Abstract
Objective: To identify the frequency and characteristics of long-term survivors of glioblastoma. Patients and Methods: Using all cases of glioblastoma with histopathological confirmation in the National Cancer Database from January 1, 2004, through December 31, 2009, clinical, institutional, and treatment-related factors were evaluated with multivariable logistic regression models so as to elucidate factors independently associated with higher than 5-year overall survival after diagnosis. Results: A total of 48,652 patients met the inclusion criteria, with 2249 (4.6%) achieving 5-year survival. Factors associated with odds of improved 5-year overall survival in multivariable analysis were younger age, female sex, less medical comorbidities, nonwhite race, highest median income quartile, left-sided tumors and tumors outside the brainstem, and treatment with radiotherapy (P<.05 for all). The percentage of patients surviving 5 years remained relatively unchanged over the 6-year study period (P=.97). Conclusion: Despite improvements in median and short-term overall survival shown in recent large clinical trials for glioblastoma, the percentage of patients with glioblastoma achieving 5-year overall survival remains low. This observation calls for the development of practice-redefining therapies and justifies the increased application of radical novel and experimental treatment paradigms for all patients with glioblastoma.
Start page
1278
End page
1286
Volume
94
Issue
7
Language
English
OCDE Knowledge area
Oncología
Neurología clínica
Scopus EID
2-s2.0-85067548238
PubMed ID
Source
Mayo Clinic Proceedings
ISSN of the container
00256196
Source funding
Novocure
Sponsor(s)
Potential Competing Interests: Dr Brown serves on the data and safety monitoring board of Novella. Dr Trifiletti has received research grants from NovoCure. The other authors report no competing interests.
Sources of information:
Directorio de Producción Científica
Scopus